Physician profile
Denis Mee-Lee
NPI 1730132416
$526,254.23
in general payments reported to CMS, 2019-2025
21 companies · $99K in 2025
The $99K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $23K · 2021: $65K · 2022: $88K · 2023: $92K · 2024: $87K · 2025: $99K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $206K · Consulting Fee: $30K · Travel and Lodging: $25K · Food and Beverage: $17K · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $205,675.75 |
| Consulting Fee | $30,110.00 |
| Travel and Lodging | $25,245.76 |
| Food and Beverage | $16,551.07 |
| Education | $124.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $108,294.84 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $107,068.70 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $91,876.96 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72,342.03 | 2020-2025 | Caplyta |
| Alkermes, INC. | $65,819.56 | 2019-2025 | Aristada, Aristada Initio, Lybalvi |
| Abbvie INC. | $56,899.08 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $10,744.28 | 2019-2022 | |
| Allergan, INC. | $7,906.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $1,324.63 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $1,218.18 | 2019-2025 | Trintellix |
| Lundbeck LLC | $888.91 | 2019-2025 | Rexulti |
| Indivior INC. | $552.43 | 2022-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $407.51 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $319.11 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $187.40 | 2023-2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $174.88 | 2020-2023 | Belsomra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $72.02 | 2025 | Rejoyn |
| Eisai INC. | $60.63 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $44.93 | 2023 | Quviviq |
| Janssen Scientific Affairs, LLC | $29.26 | 2022 | |
| Luye Pharma (USA) Ltd. | $22.84 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denis Mee-Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.